Cogent Biosciences (COGT) Retained Earnings (2017 - 2026)

Cogent Biosciences (COGT) has reported Retained Earnings for 10 consecutive years, with -$1.3 billion the latest figure, recorded in Q1 2026.

• In Q1 2026, Retained Earnings fell 38.04% year-over-year to -$1.3 billion; the TTM figure through Mar 2026 stood at -$1.3 billion (down 38.04% YoY), while the FY2025 annual figure was $355000.0, down 20.58% from the prior year.
• Retained Earnings declined to -$1.3 billion in Q1 2026 per COGT's latest filing, from $355000.0 in the prior quarter.
• Across five years, Retained Earnings topped out at $447000.0 in Q4 2024 and bottomed at -$1.3 billion in Q1 2026.
• Historically, Retained Earnings has averaged -$432.9 million across 5 years, with a median of -$336.5 million in 2022.
• Annual changes were most pronounced in 2023 — Retained Earnings soared 100.06% — and 2024, when it slumped 4137425.0%.
• Cogent Biosciences' Retained Earnings stood at -$411.2 million in 2022, then jumped by 100.06% to $246000.0 in 2023, then soared by 81.71% to $447000.0 in 2024, then dropped by 20.58% to $355000.0 in 2025, then sank by 362297.18% to -$1.3 billion in 2026.
• Business Quant data shows COGT's Retained Earnings at -$1.3 billion in Q1 2026, $355000.0 in Q4 2025, and -$1.1 billion in Q3 2025.